# A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

> **NCT02254291** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 308 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** sitagliptin

## Key facts

- **NCT ID:** NCT02254291
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-02
- **Primary completion:** 2015-11-11
- **Final completion:** 2015-11-11
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254291, "A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02254291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*